Metabolomic diferences between COVID-19 and H1N1 influenza induced ARDS

Abstract

Background Acute respiratory distress syndrome (ARDS) is a type of respiratory failure characterized by lung inflammation and pulmonary edema. Coronavirus disease 2019 (COVID-19) is associated with ARDS in the more severe cases. This study aimed to compare the specificity of the metabolic alterations induced by COVID-19 or Influenza A pneumonia (IAP) in ARDS. Methods Eighteen patients with ARDS due to COVID-19 and twenty patients with ARDS due to IAP, admitted to the intensive care unit. ARDS was defined as in the American-European Consensus Conference. As compared with patients with COVID-19, patients with IAP were younger and received more often noradrenaline to maintain a mean arterial pressure > 65 mm Hg. Serum samples were analyzed by Nuclear Magnetic Resonance Spectroscopy. Multivariate Statistical Analyses were used to identify metabolic differences between groups. Metabolic pathway analysis was performed to identify the most relevant pathways involved in ARDS development. Results ARDS due to COVID-19 or to IAP induces a different regulation of amino acids metabolism, lipid metabolism, glycolysis, and anaplerotic metabolism. COVID‐19 causes a significant energy supply deficit that induces supplementary energy-generating pathways. In contrast, IAP patients suffer more marked inflammatory and oxidative stress responses. The classificatory model discriminated against the cause of pneumonia with a success rate of 100%. Conclusions Our findings support the concept that ARDS is associated with a characteristic metabolomic profile that may discriminate patients with ARDS of different etiologies, being a potential biomarker for the diagnosis, prognosis, and management of this condition. Graphical Abstract

Plasma Oxylipins and Their Precursors Are Strongly Associated with COVID-19 Severity and with Immune Response Markers

“…Nevertheless, strong overall correlations between lipids and immune markers suggest a true disease-related context rather than an ICU bias. To isolate these effects, it is advised to recruit a control group of ICU patients who do not have COVID-19, (e.g., ARDS due to other pulmonary infections [ 75 ]). The lack of an appropriate control group is a limitation of our study, in addition to an imbalanced cohort across the disease stages and along the hospitalisation period.…”

High-Dose Vitamin C Supplementation as a Legitimate Anti-SARS-CoV-2 Prophylaxis in Healthy Subjects—Yes or No?

“…COVID-19 is a pandemic caused by coronavirus SARS-CoV-2 with mild to severe respiratory symptoms [ 48 ]. Coronaviruses and influenza are among the pandemic viruses that can cause lethal lung injuries and death from acute respiratory distress syndrome (ARDS) [ 11 , 49 ]. As was given by Earar et al [ 11 ], three clinical stages of SARS-CoV-2 infection have been described: asymptomatic stage I and II with mild and moderate symptoms, accompanied by the presence of the virus, and stage III with severe respiratory symptoms, including pneumonia, sepsis or multiple organ failure.…”

Reactive oxygen species associated immunoregulation post influenza virus infection

“…Extensive research has suggested that hyperinflammation induced by IAV is heavily involved with oxidative stress. Therefore, the elevated oxidative stress is commonly observed in IAV infected cases with severe disease progress (121)(122)(123). Consistently, several factors that are known to be associated with increased ROS levels and oxidative stress, such as chronic diseases, morbid obesity, smoking, and older age, are listed as risk factors for a more severe course on IAV infected patients (124-126).…”